FINNENCE ▪ THE WIRE FILE
THE WIRE · № 57196
News▼ Bearish
Citi tells investors it’s time to sell Moderna after 600%-plus stock gains
KINDNews
DIRECTION▼ Bearish
SOURCES1
ENTITIES2
STORY SIZESTANDALONE
FIRST SEEN2026-09-30 11:12 UTC
LAST UPDATE2026-09-30 11:12 UTC
STATEactive
01 THE MACHINE READ
WHY IT MATTERS.
A Citi sell call on Moderna after huge gains warns valuations may exceed fundamentals, pressuring biotech sentiment.
Analyst warns Moderna valuation outpaces fundamentals
CATALYST TO WATCH
Upcoming revenue and profit results
MAIN RISK
Sell call may be wrong if pipeline delivers
FULL DISPATCH
Revenue and profit forecasts fail to justify the hype baked into Moderna’s share price, according to Citi’s analysts.
02 THE STORY SO FAR
THE RECORD, IN ORDER.
STANDALONE ITEM — NOT YET FOLDED INTO A DEVELOPING STORY.
03 WHO'S INVOLVED
ENTITIES ON FILE.
AFFECTEDEli Lilly · LLY
AFFECTEDHealthcare
04 RECEIPTS
THE SOURCE RECORD.
1 SOURCES CONFIRMED05 PROPAGATION
WHAT THIS TOUCHES.
→CORRELATIONshares Healthcare
Evogene Reports Nasdaq Grants Additional 180-Day Period to Regain Minimum Bid Price Compliance2026-09-30 11:15 UTC
Evogene Reports Nasdaq Grants Additional 180-Day Period to Regain Minimum Bid Price Compliance2026-09-30 11:15 UTC
→CORRELATIONshares Healthcare
Union, governor’s office strike deal on state employee healthcare costs2026-09-29 22:54 UTC
Union, governor’s office strike deal on state employee healthcare costs2026-09-29 22:54 UTC
→CORRELATIONshares Healthcare
New Phase 3 trial: A Study of the Efficacy and Safety of Zigakibart + Atrasentan in Adult Patients With Primary IgA Nephropathy — Novartis2026-09-30 12:00 UTC
New Phase 3 trial: A Study of the Efficacy and Safety of Zigakibart + Atrasentan in Adult Patients With Primary IgA Nephropathy — Novartis2026-09-30 12:00 UTC
→CORRELATIONshares Healthcare
New Phase 3 trial: ELEVATE-LIVER: A Study to Test Whether Survodutide Helps Improve Heart Structure and Function in People With Overweight or Obesity and Fatty Liver Disease — Boehringer Ingelheim2026-09-30 12:00 UTC
New Phase 3 trial: ELEVATE-LIVER: A Study to Test Whether Survodutide Helps Improve Heart Structure and Function in People With Overweight or Obesity and Fatty Liver Disease — Boehringer Ingelheim2026-09-30 12:00 UTC
KEEP READING THE MACHINE
Summaries are generated and may contain errors — every claim links its sources.